2. Anti-infection Immunology/Inflammation
  3. Bacterial Antibiotic Interleukin Related
  4. Fusidic acid sodium salt

Fusidic acid sodium salt  (Synonyms: Sodium fusidate; SQ-16360)

Cat. No.: HY-B1350A Purity: 99.64%
SDS COA Handling Instructions

Molarity Calculator

Fusidic acid sodium salt is an orally available antibacterial agent that inhibits bacterial protein synthesis by preventing the release of translation elongation factor G (EF-G) from ribosomes. Fusidic acid sodium salt inhibits the inhibitory and activating effects of interleukins IL-1 and IL-6 on glucose-induced insulin production and exhibits antidiabetic effects in a rat model. Fusidic acid sodium salt improves the symptoms of colitis in rats and inhibits the growth of Toxoplasma gondii and Listeria monocytogenes EGD in vitro, but not in mice.

For research use only. We do not sell to patients.

Fusidic acid sodium salt Chemical Structure

Fusidic acid sodium salt Chemical Structure

CAS No. : 751-94-0

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 61 In-stock
Solution
10 mM * 1 mL in DMSO USD 61 In-stock
Solid
100 mg USD 55 In-stock
500 mg USD 110 In-stock
1 g USD 200 In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Fusidic acid sodium salt:

Fusidic acid sodium salt Related Antibodies

Top Publications Citing Use of Products

View All Antibiotic Isoform Specific Products:

View All Isoforms
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Fusidic acid sodium salt is an orally available antibacterial agent that inhibits bacterial protein synthesis by preventing the release of translation elongation factor G (EF-G) from ribosomes. Fusidic acid sodium salt inhibits the inhibitory and activating effects of interleukins IL-1 and IL-6 on glucose-induced insulin production and exhibits antidiabetic effects in a rat model. Fusidic acid sodium salt improves the symptoms of colitis in rats and inhibits the growth of Toxoplasma gondii and Listeria monocytogenes EGD in vitro, but not in mice[1][2][3][4][5][6].

IC50 & Target

IL-6

 

IL-1β

 

IL-1

 

In Vitro

Fusidic acid sodium salt has good in vitro activity (usual MIC 1mg/L) against Staphylococcus species and has modest activity (usual MIC≤ 8 mg/L) against Streptococcus and Enterococcus species[2].
At an extracellular concentration of 100 mg/L in 90% human serum, fusidic acid is bacteriostatic[2].
Fusidic acid sodium salt (0-30 μg/mL, 1-72 h) inhibits the inhibitory and activating effects of interleukin IL-1β and IL-6 on glucose-induced insulin production in rat pancreas[3].
Fusidic acid sodium salt (0-100 μg/ml, 1 h) inhibits the growth of Toxoplasma gondii in human foreskin fibroblasts (HFFs) cells with an IC50 of 4 μg/ml and a MIC of 2 μg/mL for Listeria monocytogenes EGD[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Fusidic acid sodium salt Related Antibodies
In Vivo

Fusidic acid sodium salt (20 mg/kg, s.c., three times a day, 3 days) has no effect on Toxoplasma gondii in mice[4].
Fusidic acid sodium salt (2.5 mg/ml, p.o., 200 days) has anti-diabetic effect on diabetic rats. [5].
Fusidic acid sodium salt (80 mg/kg, p.o., single dose) improves clinical, histological and serum immunological symptoms in rats with colitis[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Diabetes prone BB rats[5]
Dosage: Dissolved every second day in tap water at a concentration of 2.5 mg/ml and given to the rats as drinking water ad libitum; 200 days
Administration: Oral gavage (p.o.)
Result: Reduced the incidence of diabetes.
Animal Model: Mouse Model of Toxoplasma Gondii Infection; Mouse Model of L. monocytogenes EGD Infection[4]
Dosage: 20 mg/kg, three times a day, 3 days
Administration: Subcutaneous injection (s.c.)
Result: Reduced the survival rate of mice and caused skin eczema at the inoculation site, but had no effect on Toxoplasma and EGD in mice.
Animal Model: Dinitrobenzenesulfonic acid (DNB)-induced colitis in rats[6]
Dosage: 40, 80 mg/kg; single dose
Administration: p.o. for 40 and 80 mg/kg; Intracolonic injection for 80 mg/kg
Result: Reduced body weight losses, histological scores, as well as increased colon weights and mucosal damage. Decreased TNF-α and IFN-γ levels.
Clinical Trial
Molecular Weight

538.69

Formula

C31H47NaO6
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@@H]([C@]1([H])CC[C@]([C@@](C[C@@H]/2OC(C)=O)3C)4C)[C@H](O)CC[C@]1(C)[C@]4([H])[C@H](O)C[C@@]3([H])C2=C(C(O[Na])=O)/CC/C=C(C)\C
Structure Classification
Initial Source

Fusidium coccineum
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

H2O : ≥ 100 mg/mL (185.64 mM)

DMSO : ≥ 100 mg/mL (185.64 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.8564 mL 9.2818 mL 18.5636 mL
5 mM 0.3713 mL 1.8564 mL 3.7127 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.64 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (4.64 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (185.64 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 99.64%

SDS (394 KB)

COA (258 KB) HNMR (272 KB) LCMS (94 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 1.8564 mL 9.2818 mL 18.5636 mL 46.4089 mL
5 mM 0.3713 mL 1.8564 mL 3.7127 mL 9.2818 mL
10 mM 0.1856 mL 0.9282 mL 1.8564 mL 4.6409 mL
15 mM 0.1238 mL 0.6188 mL 1.2376 mL 3.0939 mL
20 mM 0.0928 mL 0.4641 mL 0.9282 mL 2.3204 mL
25 mM 0.0743 mL 0.3713 mL 0.7425 mL 1.8564 mL
30 mM 0.0619 mL 0.3094 mL 0.6188 mL 1.5470 mL
40 mM 0.0464 mL 0.2320 mL 0.4641 mL 1.1602 mL
50 mM 0.0371 mL 0.1856 mL 0.3713 mL 0.9282 mL
60 mM 0.0309 mL 0.1547 mL 0.3094 mL 0.7735 mL
80 mM 0.0232 mL 0.1160 mL 0.2320 mL 0.5801 mL
100 mM 0.0186 mL 0.0928 mL 0.1856 mL 0.4641 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Fusidic acid sodium salt Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Fusidic acid751-94-0Sodium fusidate SQ-16360SQ16360SQ 16360SQ-16360BacterialAntibioticInterleukin RelatedILBacteriostaticSteroidsGrowthElongationDiabetesColitisToxoplasmosisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Fusidic acid sodium salt
Cat. No.:
HY-B1350A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (394 KB) Français - FR (394 KB) Deutsch - DE (394 KB) Norwegian - NO (394 KB) Español - ES (394 KB) Swedish - SV (394 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.